Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations. | A ...

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. | For the end of this year, ...